2Carter HB;Pearson JD;Metter EJ.Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease,1992.
3Miller JI,,Ahmarm FR,Drach GW,et al.The clinical usefulness of serum prostate specific antigen after hormonaltherapy of metastatic prostate cancer. Journal d Urologie . 1992
4Mulders PF,Fernandez MP,Theeuwes AC,et al.Value of biochemical markers in the management of disseminated prostatic cancer. European Urology . 1992
5Raaijmakers R,Wildhagen M F,Ito K, et al.Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.. Urology . 2004
6Benson MC,Ring KS,Olsson CA.The determination of stage D-O carcinoma of the prostate using PSA density. . 1989
7Wang,TJ,Slawin,KM,Rittenhouse,HG.Benign prostatic hyperplasia-associated prostate-specific antigen (BPSA) shows unique immunoreactivity with anti-PSA monoclonal antibodies. European Journal of Biochemistry . 2000
8Vessella RL,Lange PH,Partin AW,et al.Probability of prostate cancerdetectionbased on results of a multicenter study using the AxSYMfreePSA and total PAS assay. Urology . 2000
9Ziade J,Leprise ES,Bansard JY,et al.Prostate specific antigen levelsin the follow up of localized prostate cancer;how does radiotherapycompare to radical prostectomy. Prostate Cancer and Prostatic Diseases . 1999
10Freedland SJ,Humphreys EB,Mangold LA,et al.Risk of prostatecancer-specific mortality following biochemical recurrence after radi-cal prostatectomy. The Journal of The American Medical Association . 2005
